BRPI9810519B8 - derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. - Google Patents

derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.

Info

Publication number
BRPI9810519B8
BRPI9810519B8 BRPI9810519A BRPI9810519A BRPI9810519B8 BR PI9810519 B8 BRPI9810519 B8 BR PI9810519B8 BR PI9810519 A BRPI9810519 A BR PI9810519A BR PI9810519 A BRPI9810519 A BR PI9810519A BR PI9810519 B8 BRPI9810519 B8 BR PI9810519B8
Authority
BR
Brazil
Prior art keywords
formula
homoerythromycin
deoxo
aza
derivatives
Prior art date
Application number
BRPI9810519A
Other languages
English (en)
Portuguese (pt)
Inventor
Scott Bronk Brian
Anthony Letavic Michael
Kaneko Takushi
Vera Yang Bingwei
Alan Glazer Edward
Cheng Hengmiao
Original Assignee
Pfizer Prod Inc
Pah Usa 15 Llc
Zoetis P Llc
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21959336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9810519(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc, Pah Usa 15 Llc, Zoetis P Llc, Zoetis Services Llc filed Critical Pfizer Prod Inc
Publication of BRPI9810519A publication Critical patent/BRPI9810519A/pt
Publication of BRPI9810519B1 publication Critical patent/BRPI9810519B1/pt
Publication of BRPI9810519B8 publication Critical patent/BRPI9810519B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI9810519A 1997-06-11 1998-05-29 derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. BRPI9810519B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4934897P 1997-06-11 1997-06-11
PCT/IB1998/000839 WO1998056802A1 (en) 1997-06-11 1998-05-29 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives

Publications (3)

Publication Number Publication Date
BRPI9810519A BRPI9810519A (pt) 2000-09-19
BRPI9810519B1 BRPI9810519B1 (pt) 2012-02-22
BRPI9810519B8 true BRPI9810519B8 (pt) 2022-11-16

Family

ID=21959336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9810519A BRPI9810519B8 (pt) 1997-06-11 1998-05-29 derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.

Country Status (49)

Country Link
US (4) US6420536B1 (https=)
EP (1) EP0988310B9 (https=)
JP (2) JP3315704B2 (https=)
KR (1) KR100396168B1 (https=)
CN (4) CN1793155B (https=)
AP (1) AP1231A (https=)
AR (1) AR013086A1 (https=)
AT (1) ATE251173T1 (https=)
AU (1) AU749816B2 (https=)
BG (1) BG64391B1 (https=)
BR (1) BRPI9810519B8 (https=)
CA (1) CA2293823C (https=)
CO (1) CO4950611A1 (https=)
CZ (1) CZ298556B6 (https=)
DE (2) DE122004000018I2 (https=)
DK (1) DK0988310T3 (https=)
DZ (1) DZ2514A1 (https=)
EA (1) EA002441B1 (https=)
EG (1) EG24081A (https=)
ES (1) ES2205487T3 (https=)
FR (1) FR04C0013I2 (https=)
GT (1) GT199800077A (https=)
HN (1) HN1998000086A (https=)
HR (1) HRP980314B1 (https=)
HU (2) HU228005B1 (https=)
ID (1) ID22992A (https=)
IL (1) IL132809A0 (https=)
IS (1) IS1998B (https=)
LU (1) LU91076I9 (https=)
MA (1) MA24564A1 (https=)
ME (1) ME00876B (https=)
MY (1) MY123354A (https=)
NL (1) NL300150I2 (https=)
NO (1) NO316911B1 (https=)
NZ (2) NZ500660A (https=)
OA (1) OA11224A (https=)
PA (1) PA8452201A1 (https=)
PE (1) PE79699A1 (https=)
PL (1) PL191601B1 (https=)
PT (1) PT988310E (https=)
RS (1) RS49675B (https=)
SI (1) SI0988310T1 (https=)
SK (1) SK284171B9 (https=)
TN (1) TNSN98082A1 (https=)
TW (1) TW472060B (https=)
UA (1) UA67744C2 (https=)
UY (1) UY25040A1 (https=)
WO (1) WO1998056802A1 (https=)
ZA (1) ZA985017B (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
EP1779853A3 (en) * 1997-09-10 2010-01-27 Merial Ltd. 9a-azalides as veterinary antimicrobial agents
ES2281136T3 (es) * 1997-09-10 2007-09-16 Merial Ltd. Uso de 9a-azalidos como agentes antimicrobiales veterinarios.
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
AP9801420A0 (en) * 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
US6043227A (en) * 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
EP1437360A3 (en) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11 Carbamates of macrolide antibacterials
US6100240A (en) * 1998-10-09 2000-08-08 Pfizer Inc Macrolide derivatives
CA2411293A1 (en) * 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
DE60038610T2 (de) * 1999-05-18 2009-06-25 Pfizer Products Inc., Groton Neue kristalline formen eines makrolidantibiotikums
HUP0201516A3 (en) * 1999-05-24 2003-03-28 Pfizer Prod Inc 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6764996B1 (en) 1999-08-24 2004-07-20 Abbott Laboratories 9a-azalides with antibacterial activity
DK1206476T3 (da) * 1999-08-24 2006-05-15 Abbott Lab 9a-azalider med antibakteriel virkning
US6608033B1 (en) 1999-08-27 2003-08-19 Pfizer Inc. Treatment or prevention of coccidiosis
BRPI0017013B1 (pt) 2000-01-27 2015-07-14 Zoetis P Llc Composição de antibiótico azalídeo e método para sua obtenção
BR0110382A (pt) * 2000-04-27 2003-06-24 Pfizer Prod Inc Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos
RU2263117C2 (ru) * 2001-04-27 2005-10-27 Пфайзер Продактс Инк. Способ получения 4"-замещенных производных 9-деоксо-9а-аза-9а-гомоэритромицина а
AU2002317415A1 (en) * 2001-08-01 2003-02-17 Pfizer Products Inc. Azalide antibiotic compositions
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
WO2005030227A1 (en) 2003-09-23 2005-04-07 Enanta Pharmaceuticals, Inc. 9a, 11-3C-BICYCLIC 9a-AZALIDE DERIVATIVES
MXPA06005639A (es) * 2003-11-21 2006-08-17 Pfizer Prod Inc Adyuvante antimicrobiano.
CN103030617A (zh) * 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
US7767797B1 (en) * 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
ATE429921T1 (de) * 2005-01-14 2009-05-15 Glaxosmithkline Zagreb 9a-carbamoyl- und thiocarbamoylazalide mit antimalariawirkung
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
JP5711135B2 (ja) 2008-10-24 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド 胃腸疾患を治療するための方法
US9937194B1 (en) * 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
MX361413B (es) 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
WO2012038372A1 (en) 2010-09-20 2012-03-29 Novartis Ag Novel process for the preparation of 9-deoxo-9a-aza- 9a-homoerythromycin a modified in the c-4'' of the cladinose ring by an epoxide group
EP2625185A4 (en) * 2010-10-10 2014-03-26 Synovo Gmbh INFLAMMATORY MAKROLIDE
WO2013004116A1 (zh) * 2011-07-06 2013-01-10 洛阳惠中兽药有限公司 C-3取代的-9-脱氧-9a-氮杂-9a-高红霉素a衍生物
CN102260306B (zh) * 2011-07-22 2012-07-18 山东鲁抗舍里乐药业有限公司 一种制备泰拉霉素的方法
EP2736915A1 (en) 2011-07-27 2014-06-04 Farma GRS, d.o.o. New crystalline forms of tulathromycin
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
CN102786569B (zh) * 2012-09-07 2016-12-07 安徽中升药业有限公司 泰拉霉素中间体及其制备方法与泰拉霉素的制备方法
AU2014239959A1 (en) 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
EP3027634B1 (en) * 2013-07-31 2018-03-21 Farma GRS, d.o.o. Process for preparation of tulathromycin
CN103497227B (zh) * 2013-09-13 2015-09-30 青岛科技大学 一种泰拉菌素中间体的制备方法
CN104725446B (zh) * 2015-03-26 2017-10-27 宁夏泰瑞制药股份有限公司 一种从泰拉霉素粗品中分离泰拉霉素a和泰拉霉素b的方法
CN104861018A (zh) * 2015-06-17 2015-08-26 瑞普（天津）生物药业有限公司 一种泰拉菌素的制备方法
CN105646617A (zh) * 2016-01-21 2016-06-08 杭州海尔希畜牧科技有限公司 一种制备泰拉霉素的方法
FR3048612B1 (fr) * 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
CN106046077B (zh) * 2016-08-04 2019-07-26 湖北美天生物科技股份有限公司 一种泰拉霉素a的合成方法
CN108003207B (zh) 2017-12-19 2019-05-10 海门慧聚药业有限公司 制备泰拉霉素的方法
CN111087433B (zh) * 2018-10-23 2023-03-21 湖北美天生物科技股份有限公司 一种泰拉霉素中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
CA2064634C (en) * 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
US5226958A (en) * 1991-04-11 1993-07-13 Pacemark, Inc. Sealant for pneumatic inner tubes and tubeless tires
EP0549040A1 (en) 1991-12-20 1993-06-30 Merck & Co. Inc. Methods of making 4" derivatives of 9-deoxo-8a-aza-8a-alkyl-8a-homoerythromycin A
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
UA70972C2 (uk) 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків

Also Published As

Publication number Publication date
CN1793155A (zh) 2006-06-28
RS49675B (sr) 2007-11-15
US20040180842A1 (en) 2004-09-16
CN1566129A (zh) 2005-01-19
CZ442199A3 (cs) 2000-07-12
HUS1200028I1 (hu) 2016-08-29
KR100396168B1 (ko) 2003-08-27
PL337505A1 (en) 2000-08-28
DZ2514A1 (fr) 2003-02-01
DK0988310T3 (da) 2003-12-15
AP1231A (en) 2003-12-11
US6777393B2 (en) 2004-08-17
HK1028048A1 (en) 2001-02-02
TNSN98082A1 (fr) 2005-03-15
CN1243766C (zh) 2006-03-01
HUP0002209A2 (hu) 2000-12-28
PL191601B1 (pl) 2006-06-30
US6420536B1 (en) 2002-07-16
NO996106L (no) 2000-02-10
DE69818665T2 (de) 2004-04-29
HK1068893A1 (en) 2005-07-29
EA199901015A1 (ru) 2000-06-26
EP0988310B1 (en) 2003-10-01
HK1088014A1 (zh) 2006-10-27
PA8452201A1 (es) 2000-05-24
ATE251173T1 (de) 2003-10-15
AU749816B2 (en) 2002-07-04
AR013086A1 (es) 2000-12-13
EP0988310B9 (en) 2006-03-08
BG64391B1 (bg) 2004-12-30
PE79699A1 (es) 1999-08-25
BRPI9810519B1 (pt) 2012-02-22
NZ500660A (en) 2002-03-01
SI0988310T1 (en) 2004-02-29
UA67744C2 (uk) 2004-07-15
BG103945A (bg) 2000-07-31
CZ298556B6 (cs) 2007-11-07
WO1998056802A1 (en) 1998-12-17
JP2000514098A (ja) 2000-10-24
AU7347598A (en) 1998-12-30
DE69818665D1 (de) 2003-11-06
HRP980314A2 (en) 1999-04-30
IS1998B (is) 2005-03-15
ZA985017B (en) 1999-12-17
CN101691390A (zh) 2010-04-07
LU91076I2 (fr) 2004-07-05
ME00876B (me) 2012-06-20
CN1172947C (zh) 2004-10-27
BRPI9810519A (pt) 2000-09-19
HN1998000086A (es) 1999-03-08
ES2205487T3 (es) 2004-05-01
NL300150I1 (nl) 2004-08-02
EP0988310A1 (en) 2000-03-29
GT199800077A (es) 1999-12-02
ID22992A (id) 1999-12-23
MY123354A (en) 2006-05-31
JP2002316933A (ja) 2002-10-31
CO4950611A1 (es) 2000-09-01
NO316911B1 (no) 2004-06-21
EA002441B1 (ru) 2002-04-25
JP3315704B2 (ja) 2002-08-19
NL300150I2 (nl) 2004-09-01
DE122004000018I1 (de) 2004-09-30
CN1793155B (zh) 2010-05-12
AP9801255A0 (en) 1998-06-30
SK284171B9 (sk) 2005-03-04
NZ514871A (en) 2003-08-29
YU58699A (https=) 2002-08-12
IL132809A0 (en) 2001-03-19
HRP980314B1 (en) 2004-04-30
TW472060B (en) 2002-01-11
KR20010013632A (ko) 2001-02-26
UY25040A1 (es) 2000-09-29
HU228005B1 (en) 2012-08-28
MA24564A1 (fr) 1998-12-31
CA2293823A1 (en) 1998-12-17
US6936592B2 (en) 2005-08-30
US20020061858A1 (en) 2002-05-23
SK168399A3 (en) 2000-11-07
CN1259136A (zh) 2000-07-05
EG24081A (en) 2008-05-11
OA11224A (en) 2003-07-16
IS5252A (is) 1999-11-16
SK284171B6 (sk) 2004-10-05
HUP0002209A3 (en) 2003-05-28
FR04C0013I1 (https=) 2004-06-11
DE122004000018I2 (de) 2011-01-13
NO996106D0 (no) 1999-12-10
US20040023896A1 (en) 2004-02-05
LU91076I9 (en) 2018-07-02
PT988310E (pt) 2003-12-31
CA2293823C (en) 2004-02-17
FR04C0013I2 (https=) 2005-10-21

Similar Documents

Publication Publication Date Title
BRPI9810519B8 (pt) derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
BR9810097A (pt) Derivados de macrolìdeos c-4-substituìdos
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR9915480A (pt) Azalìdeos de 13 membros e a sua utilização como agentes antibióticos
BR9814601A (pt) "macrólidos"
BR9802851A (pt) Antibióticos de macrolìdeo substituìdos por c-4
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BRPI0201437B8 (pt) processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos
BR9916969A (pt) Antibióticos cetólidos
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
BR9810021A (pt) Derivados 9-oxima-eritromicina
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
BR0010938A (pt) Derivados da 13-metil eritromicina
RU94022743A (ru) Амидо- или карбамидо-производные, обладающие антигиперхолестериновой активностью, и фармацевтическая композиция на их основе
BR9900856A (pt) Antibioticos macrolideos de 3,6-cetal e enol-éter
BR9812148A (pt) Derivados de eritromicina 6,9-ligados em ponte
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
BR9813317A (pt) Composto, composição farmacêutica para tratar infecções bacterianas, e, processos para tratar infecções bacterianas, e para preparar um composto
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
BR0006299A (pt) Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
AP9801235A0 (en) Erythromycin derivatives.
BR0011884A (pt) Método de tratamento da obesidade e condições comórbidas em um ser humano necessitando de tal tratamento, composto da fórmula i, produto contendo o composto da fórmula i, uso do composto da fórmula i, e, composição farmacêutica
BR9915813A (pt) Derivados da higromicina a como agentes antibacterianos

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved
B25C Requirement related to requested transfer of rights

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 860150304618 DE 23/12/2015, E NECESSARIO E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO DE CESSAO, CONFORME ART. 18 DO DEC. 13.609/43.

B25A Requested transfer of rights approved
B25G Requested change of headquarter approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/98, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2635 DE 06/07/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2146, DE 22/02/2012. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22.02.2022

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2146, DE 22/02/2012. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS, PARA MATERIA RELATIVA A PRODUTOS E PROCESSOS COM APLICACAO VETERINARIA. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.